Worldwide Argus II implantation: recommendations to optimize patient outcomes.

Autor: Ghodasra DH; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Chen A; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Arevalo JF; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Birch DG; Retina Foundation of the Southwest, Dallas, TX, USA., Branham K; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Coley B; Second Sight Medical Products, Inc., Sylmar, CA, USA., Dagnelie G; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., de Juan E; University of California, San Francisco, San Francisco, CA, USA., Devenyi RG; The University of Toronto, Toronto, Canada., Dorn JD; Second Sight Medical Products, Inc., Sylmar, CA, USA., Fisher A; Focal Point, Bristol, UK., Geruschat DR; Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Gregori NZ; Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA., Greenberg RJ; Second Sight Medical Products, Inc., Sylmar, CA, USA., Hahn P; Duke University Eye Center, Durham, NC, USA., Ho AC; Wills Eye Hospital, Philadelphia, PA, USA., Howson A; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Huang SS; Retina Center of Ohio, South Euclid, OH, USA., Iezzi R; Department of Ophthalmology, Mayo Clinic, Rochester, MN, USA., Khan N; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Lam BL; Bascom Palmer Eye Institute, University of Miami, Miami, FL, USA., Lim JI; University of Illinois at Chicago Eye and Ear Infirmary, Chicago, IL, USA., Locke KG; Retina Foundation of the Southwest, Dallas, TX, USA., Markowitz M; Private Practice, Toronto, Canada., Ripley AM; Second Sight Medical Products, Inc., Sylmar, CA, USA., Rankin M; Canadian National Institute for the Blind, Toronto, Canada., Schimitzek H; Department of Ophthalmology, RWTH Aachen University, Aachen, Germany., Tripp F; Duke University Eye Center, Durham, NC, USA., Weiland JD; Department of Ophthalmology, University of Southern California, Los Angeles, CA, USA., Yan J; Emory Eye Center, Atlanta, GA, USA., Zacks DN; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA., Jayasundera KT; Kellogg Eye Center, University of Michigan, Ann Arbor, MI, USA. thiran@umich.edu.
Jazyk: angličtina
Zdroj: BMC ophthalmology [BMC Ophthalmol] 2016 May 06; Vol. 16, pp. 52. Date of Electronic Publication: 2016 May 06.
DOI: 10.1186/s12886-016-0225-1
Abstrakt: Background: A position paper based on the collective experiences of Argus II Retinal Prosthesis System investigators to review strategies to optimize outcomes in patients with retinitis pigmentosa undergoing retinal prosthesis implantation.
Methods: Retinal surgeons, device programmers, and rehabilitation specialists from Europe, Canada, Middle East, and the United States were convened to the first international Argus II Investigator Meeting held in Ann Arbor, MI in March 2015. The recommendations from the collective experiences were collected. Factors associated with successful outcomes were determined.
Results: Factors leading to successful outcomes begin with appropriate patient selection, expectation counseling, and preoperative retinal assessment. Challenges to surgical implantation include presence of staphyloma and inadequate Tenon's capsule or conjunctiva. Modified surgical technique may reduce risks of complications such as hypotony and conjunctival erosion. Rehabilitation efforts and correlation with validated outcome measures following implantation are critical.
Conclusions: Bringing together Argus II investigators allowed the identification of strategies to optimize patient outcomes. Establishing an on-line collaborative network will foster coordinated research efforts to advance outcome assessment and rehabilitation strategies.
Databáze: MEDLINE
Externí odkaz: